Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5826599 | 0.86 | PTGS2 (0.61) | PTGS2PTGS1 | |
| SCHEMBL5826519 | 0.85 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL5826435 | 0.83 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL5826798 | 0.78 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL4721292 | 0.72 | SDHB (0.81) | PTGS2PTGS1 | |
| SCHEMBL5785867 | 0.71 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5675573 | 0.70 | PTGS2 (0.98) | PTGS2PTGS1 | |
| SCHEMBL4720369 | 0.69 | PTGS1 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5675609 | 0.69 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5787914 | 0.68 | PTGS2 (0.57) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084148-B2 | Substituted pyrimidines as selective cyclooxygenase-2 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-01 | — | — | US | claimed |
| US-20040102466-A1 | Substituted pyrimidines as selective cyclooxygenase-2 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-05-27 | — | — | US | claimed |
| US-7084148-B2 | Substituted pyrimidines as selective cyclooxygenase-2 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-20050282845-A1 | Substituted pyrimidines as selective cyclooxygenase-2 inhibitors | CARTER MALCOLM C | 2005-12-22 | — | — | US | disclosed |
| US-20040102466-A1 | Substituted pyrimidines as selective cyclooxygenase-2 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-05-27 | — | — | US | disclosed |
| EP-1313728-A1 | SUBSTITUTED PYRIMIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002018374-A1 | SUBSTITUTED PYRIMIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282845-A1 | Substituted pyrimidines as selective cyclooxygenase-2 inhibitors | PTGES2, PTGES, PTGS2 | PTGS2 3/4885PTGS1 5/4885 |
| US-20040102466-A1 | Substituted pyrimidines as selective cyclooxygenase-2 inhibitors | PTGS1, PTGS2, PTGES2 | PTGS2 2/4885PTGS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.